He Yanjing, Cai Yin, Pai Pearl Mingchu, Ren Xinling, Xia Zhengyuan
Department of Anesthesiology, The University of Hong Kong, Hong Kong, China.
Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China.
Front Pharmacol. 2021 Mar 8;12:629611. doi: 10.3389/fphar.2021.629611. eCollection 2021.
microRNAs (miRs) are short, non-coding RNAs that regulate gene expression by mRNA degradation or translational repression. Accumulated studies have demonstrated that miRs participate in various biological processes including cell differentiation, proliferation, apoptosis, metabolism and development, and the dysregulation of miRs expression are involved in different human diseases, such as neurological, cardiovascular disease and cancer. microRNA-503 (miR-503), one member of miR-16 family, has been studied widely in cardiovascular disease and cancer. In this review, we summarize and discuss the studies of miR-503 and , and how miR-503 regulates gene expression from different aspects of pathological processes of diseases, including carcinogenesis, angiogenesis, tissue fibrosis and oxidative stress; We will also discuss the mechanisms of dysregulation of miR-503, and whether miR-503 could be applied as a diagnostic marker or therapeutic target in cardiovascular disease or cancer.
微小RNA（miRs）是一类短链非编码RNA，可通过信使核糖核酸（mRNA）降解或翻译抑制来调控基因表达。大量研究表明，微小RNA参与包括细胞分化、增殖、凋亡、代谢及发育等多种生物学过程，且微小RNA表达失调与不同人类疾病相关，如神经疾病、心血管疾病及癌症。微小RNA-503（miR-503）作为miR-16家族成员之一，已在心血管疾病和癌症领域得到广泛研究。在本综述中，我们总结并讨论了miR-503的相关研究，以及miR-503如何从疾病病理过程的不同方面（包括致癌作用、血管生成、组织纤维化和氧化应激）调控基因表达；我们还将讨论miR-503失调的机制，以及miR-503是否可作为心血管疾病或癌症的诊断标志物或治疗靶点。
